{"text": ["Financial", "Exchange", "Stock", "Talk:", "Dividend", "Sensei", "On", "AbbVie"], "created_at": "2019-04-30 22:07:54"}
{"text": ["Financial", "Exchange", "Stock", "Talk:", "Dividend", "Sensei", "On", "AbbVie"], "created_at": "2019-04-30 22:07:54"}
{"text": ["Top", "Stock", "Reports", "for", "Facebook,", "Comcast", "&", "AbbVie"], "created_at": "2019-04-30 18:52:06"}
{"text": ["Neurocrine", "Biosciences", "Has", "Robust", "Late-Stage", "Pipeline"], "created_at": "2019-04-30 14:35:02"}
{"text": ["European", "Commission", "Approves", "SKYRIZI\u2122", "(risankizumab)", "for", "the", "Treatment", "of", "Moderate", "to", "Severe", "Plaque", "Psoriasis"], "created_at": "2019-04-30 11:45:00"}
{"text": ["AbbVie\u2019s", "Guidance", "for", "Second", "Quarter", "of", "Fiscal", "2019"], "created_at": "2019-04-30 11:32:21"}
{"text": ["AbbVie", "to", "Present", "New", "and", "Updated", "Data", "of", "Investigational", "Medicines", "for", "Parkinson's", "Disease", "and", "Multiple", "Sclerosis", "at", "2019", "American", "Academy", "of", "Neurology", "Annual", "Meeting"], "created_at": "2019-04-30 11:08:00"}
